Bioxytran (BIXT) Intangibles (2020 - 2026)
Bioxytran (BIXT) posted Intangibles of $152206.0 for Q1 2026, up 4.91% sequentially from $145087.0 in Q4 2025, and down 0.8% YoY from $153434.0 in Q1 2025.
Bioxytran (BIXT) Intangibles (2020 - 2026) Analysis & Trends
Bioxytran has reported Intangibles for 7 years, with the latest figure at $152206.0 in Q1 2026.
- Quarterly Intangibles fell 0.8% year-over-year to $152206.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $152206.0 (down 0.8% YoY) and the FY2025 annual result came in at $145087.0, up 8.65% from the prior year.
- Intangibles improved to $152206.0 in Q1 2026 per BIXT's latest filing, from $145087.0 in the prior quarter.
- Over five years, Intangibles peaked at $168596.0 in Q2 2025 and troughed at $67548.0 in Q2 2022.
- A 5-year average of $115997.2 and a median of $116919.0 in 2023 frame the typical range for Intangibles.
- The sharpest annual moves came in 2022 and 2026: Intangibles jumped 306.68% in 2022, then fell 0.8% in 2026.
- Over 5 years, Intangibles stood at $79179.0 in 2022, then jumped by 58.15% to $125225.0 in 2023, then climbed by 6.64% to $133540.0 in 2024, then gained by 8.65% to $145087.0 in 2025, then advanced by 4.91% to $152206.0 in 2026.
- According to Business Quant data, Intangibles over the past three periods registered $152206.0, $145087.0, and $141795.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 412.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.31 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 266.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 60.96 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | - |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 93.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | - |
| 10 | Bioxytran | 2.47 Mn | 2.22 Mn | - | 195,120.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 152,206.00 |
| Dec 31, 2025 | 145,087.00 |
| Sep 30, 2025 | 141,795.00 |
| Jun 30, 2025 | 168,596.00 |
| Mar 31, 2025 | 153,434.00 |
| Dec 31, 2024 | 133,540.00 |
| Sep 30, 2024 | 124,336.00 |
| Jun 30, 2024 | 115,031.00 |
| Mar 31, 2024 | 115,516.00 |
| Dec 31, 2023 | 125,225.00 |
| Sep 30, 2023 | 116,919.00 |
| Jun 30, 2023 | 104,226.00 |
| Mar 31, 2023 | 83,890.00 |
| Dec 31, 2022 | 79,179.00 |
| Sep 30, 2022 | 77,082.00 |
| Jun 30, 2022 | 67,548.00 |
| Mar 31, 2022 | 68,343.00 |
| Dec 31, 2021 | 46,932.00 |
| Sep 30, 2021 | 18,954.00 |
| Jun 30, 2021 | 18,954.00 |